Taysha Gene Therapies, Inc. (TSHA) Free cash flow 2020–2025
Taysha Gene Therapies, Inc. (TSHA) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$93.8MFY2025 · since FY2020: -$30.8M → -$93.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$93.8M | -15.0% |
| FY2024 | -$81.6M | -6.1% |
| FY2023 | -$76.9M | +29.5% |
| FY2022 | -$109.0M | +17.6% |
| FY2021 | -$132.3M | -329.5% |
| FY2020 | -$30.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice